Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Kazuho Shimura"'
Autor:
Kentaro Mizuhara, Tsutomu Kobayashi, Mitsushige Nakao, Ryoichi Takahashi, Hiroto Kaneko, Kazuho Shimura, Koichi Hirakawa, Nobuhiko Uoshima, Katsuya Wada, Eri Kawata, Reiko Isa, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Akiko Yoneda, Akihide Watanabe, Chie Sotozono, Junya Kuroda
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3134-3144 (2023)
Abstract Background Primary ocular adnexal mucosa‐associated lymphoid tissue (MALT) lymphoma (POAML) is the most common subtype of indolent ocular adnexal lymphomas. Although radiotherapy (RT) is the standard of care for localized POAML, it can occ
Externí odkaz:
https://doaj.org/article/b460dddda59b42078883f9d92b82552e
Autor:
Yuka Kawaji‐Kanayama, Tsutomu Kobayashi, Ayako Muramatsu, Hitoji Uchiyama, Nana Sasaki, Nobuhiko Uoshima, Mitsushige Nakao, Ryoichi Takahashi, Kazuho Shimura, Hiroto Kaneko, Miki Kiyota, Katsuya Wada, Yoshiaki Chinen, Koichi Hirakawa, Shin‐ichi Fuchida, Chihiro Shimazaki, Yayoi Matsumura‐Kimoto, Shinsuke Mizutani, Taku Tsukamoto, Yuji Shimura, Shigeo Horiike, Masafumi Taniwaki, Junya Kuroda, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators
Publikováno v:
Cancer Reports, Vol 5, Iss 2, Pp n/a-n/a (2022)
Abstract Background Combinatory strategies with carfilzomib (CFZ), a second‐generation proteasome inhibitor, plus dexamethasone (DEX) with or without lenalidomide (LEN) have shown promising efficacy for patients with relapsed/refractory multiple my
Externí odkaz:
https://doaj.org/article/bdff3f7ce0164c809dccfaff7fdd38f3
Autor:
Hiroto Kaneko, Kazuho Shimura, Mihoko Yoshida, Yosuke Matsumoto, Tsutomu Kobayashi, Hitoji Uchiyama, Junya Kuroda, Masafumi Taniwaki
Publikováno v:
International Journal of Hematology-Oncology and Stem Cell Research, Vol 16, Iss 1 (2022)
Background: In the current Japanese aging society, a high number of very elderly patients (age ranged from 80 to 93) with diffuse large B-cell lymphoma (DLBCL, most frequent hematological malignancy), who require chemotherapy are encountered. However
Externí odkaz:
https://doaj.org/article/1c2ccacab0fe45878d64dbf7d7152a85
Autor:
Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 10, Iss 1, Pp e2018014-e2018014 (2018)
Elotuzumab, targeting signaling lymphocytic activation molecule family 7 (SLAMF7), has been approved in combination with lenalidomide and dexamethasone (ELd) for relapsed/refractory multiple myeloma (MM) based on the findings of the phase III randomi
Externí odkaz:
https://doaj.org/article/c29b13fc01f34a618bb25d06f8b63492
Autor:
Kensuke Matsuda, Yosuke Matsumoto, Mihiko Yoshida, Kazuho Shimura, Hiroto Kaneko, Tohru Inaba, Shigeo Horiike, Junya Kuroda, Masafumi Taniwaki
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 9, Iss 1, Pp e2017054-e2017054 (2017)
Hairy B-cell lymphoproliferative disorder (HBLD) is one of chronic polyclonal B-cell lymphocytosis. We report a 47-year-old female Japanese patient diagnosed as having HBLD based on lymphocytosis with hairy cell appearance and characteristic phenotyp
Externí odkaz:
https://doaj.org/article/0231e8b933714b3e86d0d24131334463
Autor:
Akio Onishi, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, Taku Tsukamoto, Takahiro Fujino, Akihiro Miyashita, Daichi Nishiyama, Kazuho Shimura, Hiroto Kaneko, Eri Kawata, Ryoichi Takahashi, Tsutomu Kobayashi, Hitoji Uchiyama, Nobuhiko Uoshima, Yoko Nukui, Yuji Shimura, Tohru Inaba, Junya Kuroda
Publikováno v:
Infection and Drug Resistance. 16:509-519
Akio Onishi,1 Yayoi Matsumura-Kimoto,1,2 Shinsuke Mizutani,1 Taku Tsukamoto,1 Takahiro Fujino,1 Akihiro Miyashita,1,3 Daichi Nishiyama,4 Kazuho Shimura,5 Hiroto Kaneko,5 Eri Kawata,6 Ryoichi Takahashi,7 Tsutomu Kobayashi,1,8 Hitoji Uchiyama,8 Nobuhik
Autor:
Kentaro Mizuhara, Tsutomu Kobayashi, Mitsushige Nakao, Ryoichi Takahashi, Hiroto Kaneko, Kazuho Shimura, Koichi Hirakawa, Nobuhiko Uoshima, Katsuya Wada, Eri Kawata, Reiko Isa, Takahiro Fujino, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Akiko Yoneda, Akihide Watanabe, Chie Sotozono, Junya Kuroda
Publikováno v:
Cancer medicineREFERENCES.
Primary ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (POAML) is the most common subtype of indolent ocular adnexal lymphomas. Although radiotherapy (RT) is the standard of care for localized POAML, it can occasionally lead to perm
Autor:
Ayako, Muramatsu, Tsutomu, Kobayashi, Yuka, Kawaji-Kanayama, Hitoji, Uchiyama, Nana, Sasaki, Nobuhiko, Uoshima, Mitsushige, Nakao, Ryoichi, Takahashi, Kazuho, Shimura, Hiroto, Kaneko, Miki, Kiyota, Katsuya, Wada, Yoshiaki, Chinen, Koichi, Hirakawa, Shin-Ichi, Fuchida, Chihiro, Shimazaki, Shinsuke, Mizutani, Taku, Tsukamoto, Yuji, Shimura, Masafumi, Taniwaki, Satoshi, Teramukai, Junya, Kuroda
Publikováno v:
Leukemialymphoma. 63(7)
Carfilzomib (CFZ) constitutes powerful combinatory therapy for relapsed/refractory multiple myeloma (RRMM); however, cardiovascular adverse events (CVAEs) have been shown as major treatment obstacles with the use of CFZ. Along with our multi-institut
Autor:
Ryo Takagi, Tsutomu Kobayashi, Shin-ichi Fuchida, Kazuho Shimura, Nobuhiko Uoshima, Hiroto Kaneko, Junya Kuroda, Yuji Shimura, Taku Tsukamoto, Katsuya Wada, Masafumi Taniwaki, Mitsushige Nakao, Miki Kiyota, Kazuna Tanba, Chihiro Shimazaki, Isao Yokota, Shigeo Horiike, Yutaka Kobayashi, Hitoji Uchiyama, Yoshiaki Chinen
Publikováno v:
Leukemia & Lymphoma. 61:3378-3386
Extended post-therapy long-term survival of patients with diffuse large B cell lymphoma (DLBCL) may also lead to an increase of late adverse events. We retrospectively investigated the frequency and clinical manifestation of second primary malignancy
Autor:
Yuka, Kawaji-Kanayama, Ayako, Muramatsu, Nana, Sasaki, Kazuho, Shimura, Miki, Kiyota, Shinichi, Fuchida, Reiko, Isa, Takahiro, Fujino, Yayoi, Matsumura-Kimoto, Taku, Tsukamoto, Yoshiaki, Chinen, Shinsuke, Mizutani, Mitsushige, Nakao, Hiroto, Kaneko, Eri, Kawata, Koichi, Hirakawa, Ryoichi, Takahashi, Chihiro, Shimazaki, Hitoji, Uchiyama, Nobuhiko, Uoshima, Yuji, Shimura, Tsutomu, Kobayashi, Masafumi, Taniwaki, Junya, Kuroda
Publikováno v:
International journal of hematology. 115(3)
We conducted a post hoc analysis of our previous pilot observational study on the efficacy and safety of carfilzomib (CFZ)-containing therapy in 50 patients with relapsed/refractory multiple myeloma in routine practice to clarify the relationships be